Trial Profile
Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease in Conjunction With Long-term Outcome
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms RUN-CD Study
- 23 May 2021 Results (n=616) assessing the HRQoL, effectiveness, clinical and steroid-free remission at week 16, of UST induction therapy vs other biologics in crohns disease, presented at the Digestive Disease Week 2021.
- 12 Jul 2018 Planned End Date changed from 30 May 2022 to 31 Mar 2023.
- 12 Jul 2018 Planned primary completion date changed from 31 Mar 2022 to 31 Mar 2023.